

S2 Table. Infection rate with *Taenia solium* taeniasis

Table A. Results of the studies that tested mass drug administration (with or without selective chemotherapy)

Study ID	Country	Study Design	Drug	Dose	Time of follow-up (months)	Prevalence at baseline (n/N)	Prevalence at follow-up (n/N)	Total N	Relative reduction in prevalence
Allan 1997	Guatemala	BA	NICL	2g	10	3.54% (56/1582)	1.0% (11/1116)	1116	72%
Braae 2017									96%
Annual MDA children	Tanzania	CBA	PZQ, NICL, PZQ	40mg/kg	9-10	2.31% (22/951)	0.1% (1/1070)	951	
Biennial MDA children			PZQ, NICL, PZQ	40mg/kg	9-10	1.25% (11/880)	0.4% (4/1076)	880	70%
SC adults (annual MDA)			NICL, PZQ	2g, 10mg/kg	9-10	4.10% (23/561)	1.8% (8/444)	444	56%
SC adults (biennial MDA)			NICL, PZQ	2g, 10mg/kg	9-10	1.77% (11/621)	0.7% (3/425)	425	60%
Cruz 1989	Ecuador	BA	PZQ	5mg/kg	12	1.55% (148/9529)	0.0% (0/539)	539	100%
Diaz Camacho 1991	Mexico	BA	NICL, PZQ	2g, 10mg/kg	12	1.32% (4/302)	0.0% (0/283)	283	100%
Sarti 2000 ^a	Mexico	BA	PZQ	5mg/kg	42	1.13% (21/1865)	0.5% (3/605)	605	56%
Steinmann 2008 ^b	China	RCT	ALB	400mg	1	40.91% (27/66)	25.8% (17/66)	66	37%
Steinmann 2011									
single dose ^c	China	RCT	ALB	400mg	1	13.41% (11/82)	7.3% (6/82)	82	45%
triple dose ^d			ALB	3x400mg	1	10.29% (7/68)	0.0% (0/68)	68	100%
Steinmann 2015									
Annual MDA ^e	China	CBA	ALB	400mg	24	14.80% (14.8/100)	6.7% (6.7/100)	100	55%
6-monthly MDA ^e			ALB	400mg	24	13.70% (13.7/100)	10.6% (10.6/100)	100	23%

ALB - albendazole; BA - before-after study; CBA - controlled before-after study; MDA – mass drug administration; NICL - niclosamide; PZQ - praziquantel; RCT - randomized controlled trial; SC – selective chemotherapy

a – Prevalence at the 6-month follow-up was 0.53% (7/1311), with a relative reduction in prevalence of 53%

b – 10 ‘new’ positive infections at follow-up were added to the number positive at baseline. Cure rate: 37% (10/27)

c – 1 ‘new’ positive infection at follow-up was added to the number positive at baseline. Cure rate: 45% (5/11)

d – Cure rate: 100% (7/7); Relative risk 2.2 (95%CI 0.7-3.7) for cure with triple dose versus single dose ALB 400mg.

e – Results at 2-year follow-up; Total N of 100 is approximate

Table B. Results of the studies that tested selective chemotherapy

Study ID	Country	Study Design	Drug	Dose	Time of final follow-up (days)	Total N	N cured	Cure rate
Bustos 2012	Peru	BA	NICL	2g	90	68	53	77.9%
de Kaminsky 1991	Honduras	BA	ALB	3x400mg	90	56	56	100.0%
Groll 1980	Various	CBA	PZQ	10mg/kg	90	33	33	100.0%
			PZQ	5mg/kg	90	9	6	66.7%
Jagota 1986	India	CBA	ALB	400mg	21 ^a	37	24	64.9%
			ALB	3x400mg	21 ^a	37	32	86.5%
Kumar 2014	India	BA	PZQ	10mg/kg	14-21	57	57	100.0%
Moreira 1983	Brazil	BA	PZQ	10mg/kg	90	31	31	100.0%
Rim 1979	Korea	CBA	PZQ	10mg/kg	90	27	27	100.0%
			PZQ	5mg/kg	90	26	25	96.2%
Taylor 1995	South Africa	BA	PZQ	40mg/kg	45	3	3	100.0%
Varma 1990	India	CBA	NICL	2g	90	38	36	94.7%
O'Neal 2014 ^b	Peru	CT	NICL	2g	120 (after final treatment)	0.7% (5/703) intervention vs 1.6% (9/555) control, adjusted prevalence ratio 0.28 (95%CI 0.08-0.91)		

ALB - albendazole; BA - before-after study; CBA - controlled before-after study; CT - controlled trial; NICL - niclosamide; PZQ - praziquantel

a – Some participants were also tested at 90 days post-treatment

b – Figures are prevalence of confirmed taeniasis at follow-up